Key Highlights
- B. Riley reduced Oklo’s price target to $92 from $129 while maintaining its Buy recommendation
- Needham slashed its forecast from $135 to $73 but retained a Buy rating, suggesting potential 20% gains
- Craig-Hallum dropped its target to $71 from $87, keeping a Hold rating due to escalating capital requirements
- CEO Jacob Dewitte and CFO Richard Bealmear each offloaded approximately 72,000 shares at $60 per share on March 13
- Insider transactions totaling roughly $170M have occurred over the last 90 days
- Oklo’s Atomic Alchemy division secured a DOE Nuclear Safety Design Agreement and an NRC materials license
The past six months have been challenging for Oklo, with shares currently trading around $60.76. The nuclear energy developer has experienced a 42% decline during this period, significantly below its 52-week peak of $193.84.
Following the company’s Q4 2025 financial results, multiple Wall Street firms adjusted their price projections downward this week. While targets dropped across the board, most analysts remain optimistic about the company’s long-term prospects.
B. Riley revised its forecast to $92 from $129 while maintaining a Buy stance. The firm highlighted meaningful operational achievements: Department of Energy approvals for the Aurora facility at Idaho National Laboratory, a prepayment deal with Meta covering up to 1.2 gigawatts in Ohio, initial fuel facility development, and key regulatory wins for the Atomic Alchemy isotope division.
Needham maintained its Buy recommendation despite significantly reducing its target from $135 to $73. Even at this lower projection, the target suggests approximately 20% potential upside from present levels. The consensus Street target hovers around $94.80 with a “Moderate Buy” rating overall.
Craig-Hallum adopted a more conservative stance, maintaining its Hold rating while trimming the target from $87 to $71. The firm adjusted its financial models to reflect elevated operating costs, higher capital expenditures, and revised projections for future funding requirements. Craig-Hallum excluded anticipated 2026 isotope revenues—expected to fall under $5 million—from its calculations until greater visibility emerges.
Funding Requirements and Executive Stock Sales Pressure Shares
Oklo finished Q4 2025 holding $1.4 billion in cash reserves. Following the quarter’s conclusion, the company secured another $1.2 billion in funding. Management provided 2026 guidance projecting operating cash consumption between $80 million and $100 million, alongside investing cash usage of $350 million to $450 million.
Despite substantial cash holdings, the company recorded an EBITDA deficit of $97 million across the trailing twelve months and a full-year 2025 operating loss totaling $139.3 million. Wall Street analysts don’t anticipate profitability arriving this year.
Compounding investor concerns, CEO Jacob Dewitte disposed of approximately 72,960 shares on March 13 at $60 each, generating proceeds of roughly $4.38 million. CFO Richard Bealmear sold 72,090 shares the same day at an identical price, totaling about $4.33 million. Throughout the previous 90 days, company insiders have collectively sold approximately 2.07 million shares valued at roughly $170 million. Insiders retain an 18.9% ownership stake.
Operational and Regulatory Milestones Achieved
Not all developments have been negative. Oklo’s Atomic Alchemy unit obtained a DOE Nuclear Safety Design Agreement for its Groves isotopes test reactor. The subsidiary also secured an NRC materials and isotope license—marking Oklo’s first NRC license obtained via an acquired entity.
The Aurora reactor received initial design approval from the Department of Energy, an essential milestone for advancing a 1.2-gigawatt power supply agreement with Meta, scheduled for delivery by 2034.
William Blair confirmed an Outperform rating. Cantor Fitzgerald maintained an Overweight designation with a $122 price objective. Barclays holds an Overweight rating with an $82 target. Bank of America rates the stock Buy with a $127 target.
Oklo’s 50-day moving average currently sits at $75.08, while its 200-day moving average rests at $95.27. The company’s market capitalization stands at approximately $9.49 billion.
